0.44  0.009 (2.14%)		06-12 16:00
Open: 0.44 High: 0.4545 Volume: 55,527		Pre. Close: 0.4308 Low: 0.4315 Market Cap: 62(M)

Short term
Mid term
Targets	6-month :	0.61	1-year :	0.67
Resists	First :	0.52	Second :	0.57
Pivot price	0.45
Supports	First :	0.43	Second :	0.35
MAs	MA(5) :	0.44	MA(20) :	0.45
	MA(100) :	0.54	MA(250) :	0.62
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	9.6	D(3) :	9.8
RSI	RSI(14): 35.6
52-week	High :	0.94	Low :	0.43

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ XTNT ] has closed above bottom band by 16.6%. Bollinger Bands are 52.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.46 - 0.46	0.46 - 0.46
Low:	0.42 - 0.43	0.43 - 0.43
Close:	0.44 - 0.44	0.44 - 0.44

Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.

Sun, 17 May 2026
Xtant Medical Holdings stock (US98420U1051): guidance raised after Q1 update moves spinal implant st - AD HOC NEWS

Fri, 15 May 2026
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Thu, 14 May 2026
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2026 Earnings Call Transcript - Insider Monkey

Wed, 13 May 2026
XTNT: Q1 2026 revenue dropped 37% and net loss reached $3.1M amid asset sales and reimbursement shifts - TradingView

Mon, 13 Apr 2026
Xtant adds 20-person sales team in HEMOBLAST U.S. deal - Stock Titan

Mon, 02 Mar 2026
Xtant Medical Finalizes Companion Spine Transactions - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Medical - Devices
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.